Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

NRx Pharmaceuticals Publishes Shareholder Update Letter; Update Highlights Potential Implications Of The Company’s Recent Activities At The Annual Meeting Of The American Society Of Clinical Psychopharmacology

By Benzinga Newsdesk
June 10, 8:34 AM
The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of care for treating

NRXP

Read More
1 minute read

NRx Pharmaceuticals Presents Landmark Trial Of NRX-101 In Suicidal Bipolar Depression At The ASCP Annual Meeting: NRX-101 Is The First Oral Antidepressant Demonstrated To Reduce Suicidality In Bipolar Depression

By Benzinga Newsdesk
May 28, 8:47 AM
Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior"NRX-101

NRXP